Syfovre-related vision loss has been reported in patients after the first time they used a Syfovre injection treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
In mid-July 2023 the American Society of Retinal Specialists (ASRS) issued a warning letter about Syfovre-related vision loss as well as some other eye adverse reactions.
This still-developing Syfovre safety issue was next addressed by a so-called “Dear Doctor” letter that was sent to ophthalmologists by Apellis Pharmaceuticals, Inc., the drug company responsible for Syfovre, later in July 2023, after the ASRS letter.
From this July 28, 2023 item, “First-to-Market Edge for Apellis’s Syfovre in Geographic Atrophy Diminished in the Face of an Unexpected Safety Signal”, we get the following information:
According to the American Society of Retina Specialists (ASRS) Research and Safety in Therapeutics (ReST) Committee, ophthalmologists have reported cases of intraocular inflammation (IOI) following the administration of Syfovre. In addition to mild-moderate IOI, these reports also include severe IOI, retinal vasculitis, and occlusive retina vasculitis (six cases at the time of writing). These events occurred between 7 and 13 days after the initial dose of Syfovre was administered.
We are investigating Syfovre-related vision loss cases as drug injury lawsuits that would be filed against Apellis for patients who developed occlusive retinal vasculitis or eye inflammation after receiving a Syfovre injection.
We will continue to monitor this Syfovre safety issue and report significant developments.
[View article at original source]Syfovre
Free Case Evaluation
Strictly Confidential, No Obligation